多药耐药相关蛋白基因在非小细胞肺癌表达的临床意义

Clinical significance of multidrug resistance associated protein(MRP) gene expression in non small cell lung cancer

目的探索多药耐药相关蛋白（ＭＲＰ）在非小细胞肺癌（ＮＳＣＬＣ）的表达，以及与病理类型、病期及预后的关系。方法以原位杂交法检测冰冻ＮＳＣＬＣ组织。结果全组５８例ＮＳＣＬＣ、ＭＲＰｍＲＮＡ总表达率为７４．１％，鳞癌为７２．０％，腺癌为７３．３％。ＭＲＰ的表达与病理类型、ＴＮＭ分期及分化程度无关。４７例接受化疗的ＮＳＣＬＣ中，３５例ＭＲＰ表达（＋～＋＋）者生存率明显低于ＭＲＰ表达（－）者（Ｐ＜０．０５），中位生存期分别为８．７个月和２１个月（Ｐ＜０．０５）；１２例ＭＲＰ表达（＋～＋＋）鳞癌生存率亦明显低于７例ＭＲＰ表达（－）者（Ｐ＜０．０５），中位生存期分别为６个月和１９．５个月（Ｐ＜０．０５）。

Objective To investigate expression of multidrug resistance associated protein (MRP) in non small cell lung cancer and its relation to histological type, TNM staging and prognosis. Methods In situ hybridization was used to examine mRNA expression of MRP. Results The overall positive rate of MRP expression was 74.1%, with 73.3% and 72.0% in adenocarcinoma and squamous cell carcinoma, respectively. The expression of MRP was not related to histological subtypes, TNM staging and cell differentiation. In 47 patients who received chemotherapy, 35 patients with positive MRP expression(+～++) showed worse prognosis than in those with negative expression ( P <0.05). The median survival time was 8.7 months and 21 months in patients with positive and negative MRP expession, respectively. In patients with squamous cell carcinoma, the survival rate was significantly lower in patients ( n =12) with positive MRP expression than in those ( n =7) with negative MRP expression ( P <0.05). Their median survival time was 6 months and 19.5 months, respectively ( P < 0.05). Conclusion The expression of MRP gene is negatively correlated with survival of patients with squamous cell carcinoma, but not adenocarcinoma, who received chemotherapy.